Hospital
Prime Healthcare Services Landmark LLC
Prime Healthcare Services Landmark LLC was paid $26.18M by Medicaid between Jan 2018 and Dec 2024, across 203 billing codes. Its largest line is 99283, emergency room visit (moderate) — 9.3% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES LANDMARK LLC
WOONSOCKET, RI 02895
WOONSOCKET, RI 02895
33aNPI1699752923assigned 12/28/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$26.18M
24GClaims224,979
24DCodes billed203
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Rhode Island
Rank by total paid#4 of 11
Median peer was paid$12.56M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 55,869 | $5.59M | |
| 2019 | 79,216 | $9.61M | |
| 2020 | 23,779 | $2.50M | |
| 2021 | 20,501 | $1.74M | |
| 2022 | 18,343 | $2.09M | |
| 2023 | 13,606 | $2.32M | |
| 2024incomplete | 13,665 | $2.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.3% | 11,246 | 9,051 | $2.44M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 10,215 | 8,031 | $2.35M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.5% | 9,268 | 7,221 | $2.21M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.8% | 17,479 | 12,753 | $1.01M |
| 80053 | Comprehensive metabolic panel | 3.2% | 10,870 | 7,943 | $837K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 5,289 | 3,974 | $784K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 2,697 | 1,576 | $675K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.6% | 3,895 | 2,750 | $669K |
| 71046 | Radiologic examination, chest; 2 views | 2.0% | 5,388 | 4,230 | $534K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 3,693 | 2,252 | $505K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 6,442 | 4,533 | $478K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.8% | 3,142 | 2,006 | $471K |
191 more codes
| J7030 | Infusion, normal saline solution , 1000 cc | 1.7% | 4,563 | $452K |
| 36415 | Collection of venous blood by venipuncture | 1.7% | 8,920 | $445K |
| G0378 | Hospital observation service, per hour | 1.7% | 1,037 | $441K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.7% | 1,424 | $441K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 3,250 | $434K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.6% | 1,123 | $409K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.4% | 2,077 | $364K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.4% | 4,774 | $356K |
| J3490 | Unclassified drugs | 1.2% | 3,244 | $326K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.2% | 1,302 | $321K |
| 84484 | 1.2% | 4,620 | $321K | |
| 83690 | 1.2% | 4,533 | $317K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.2% | 2,656 | $315K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 2,447 | $279K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,344 | $260K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,164 | $253K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,574 | $253K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,873 | $253K |
| 81001 | <1% | 4,013 | $248K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,012 | $207K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,766 | $198K |
| 59025 | Fetal non-stress test | <1% | 740 | $182K |
| 73630 | <1% | 1,640 | $179K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 731 | $176K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 423 | $166K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,163 | $163K |
| 81003 | <1% | 2,396 | $153K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,823 | $147K |
| 81025 | <1% | 1,659 | $145K | |
| 82962 | <1% | 1,828 | $144K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,234 | $134K |
| 87070 | <1% | 3,064 | $130K | |
| 73610 | <1% | 1,065 | $127K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 771 | $121K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 402 | $118K |
| 76830 | Ultrasound, transvaginal | <1% | 530 | $115K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,447 | $112K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,433 | $112K |
| 76801 | <1% | 481 | $111K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 674 | $111K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 559 | $100K |
| 80061 | Lipid panel | <1% | 1,182 | $97K |
| 73130 | <1% | 894 | $94K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,447 | $93K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,143 | $92K |
| 85610 | <1% | 1,511 | $91K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,089 | $84K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,041 | $84K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 859 | $83K |
| 73030 | <1% | 702 | $74K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 140 | $73K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 431 | $68K |
| 85730 | <1% | 791 | $66K | |
| 83735 | <1% | 820 | $66K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 391 | $64K |
| 86900 | <1% | 761 | $60K | |
| 76536 | <1% | 270 | $60K | |
| 87081 | <1% | 646 | $60K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 252 | $59K |
| 73564 | <1% | 415 | $57K | |
| 73110 | <1% | 578 | $57K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,113 | $56K |
| 73560 | <1% | 475 | $56K | |
| J2704 | Injection, propofol, 10 mg | <1% | 420 | $54K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 762 | $54K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 559 | $53K |
| 83605 | <1% | 583 | $49K | |
| 86850 | <1% | 657 | $48K | |
| 73562 | <1% | 482 | $47K | |
| 87186 | <1% | 1,028 | $46K | |
| 85027 | <1% | 779 | $43K | |
| 86901 | <1% | 761 | $43K | |
| 72110 | <1% | 326 | $42K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 149 | $41K |
| 99223 | Prolong inpt eval add15 m | <1% | 314 | $40K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 564 | $39K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 194 | $38K |
| 80076 | <1% | 590 | $36K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 575 | $34K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 558 | $34K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 757 | $33K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 385 | $32K |
| 87428 | <1% | 201 | $32K | |
| 88142 | <1% | 643 | $31K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 170 | $31K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 423 | $31K |
| 73140 | <1% | 308 | $30K | |
| 87205 | <1% | 516 | $28K | |
| 87184 | <1% | 794 | $27K | |
| 83880 | <1% | 470 | $26K | |
| 84702 | <1% | 233 | $26K | |
| 85007 | <1% | 636 | $25K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 318 | $24K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 340 | $24K |
| 73502 | <1% | 270 | $23K | |
| 76770 | <1% | 117 | $23K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 263 | $23K |
| 87480 | <1% | 426 | $22K | |
| 76642 | <1% | 133 | $22K | |
| 87510 | <1% | 422 | $22K | |
| 87660 | <1% | 422 | $22K | |
| 86803 | <1% | 351 | $21K | |
| 84145 | <1% | 149 | $21K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 534 | $20K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 336 | $19K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 77 | $19K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 32 | $19K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 25 | $18K |
| 80320 | <1% | 191 | $18K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 90 | $18K |
| 85379 | <1% | 364 | $17K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 331 | $16K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 253 | $16K |
| 87806 | <1% | 226 | $16K | |
| 94762 | <1% | 233 | $14K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 115 | $14K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 241 | $13K |
| 74019 | <1% | 91 | $13K | |
| 93971 | <1% | 61 | $13K | |
| 73080 | <1% | 127 | $13K | |
| 80329 | <1% | 72 | $13K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 53 | $13K |
| 72100 | <1% | 155 | $13K | |
| A6531 | Gradient compression stocking, below knee, 30-40 mmhg, used as a surgical dressing, each | <1% | 47 | $13K |
| 84439 | <1% | 264 | $13K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 46 | $12K |
| 71250 | <1% | 52 | $12K | |
| 86703 | <1% | 374 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 49 | $12K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 15 | $12K |
| 74018 | <1% | 143 | $12K | |
| 86592 | <1% | 421 | $11K | |
| 96376 | <1% | 150 | $11K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 125 | $11K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 65 | $10K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 322 | $9K |
| 87040 | <1% | 37 | $9K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 211 | $8K |
| 85651 | <1% | 293 | $8K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 152 | $8K |
| 94760 | <1% | 63 | $7K | |
| 87340 | <1% | 149 | $7K | |
| 96367 | <1% | 76 | $7K | |
| 86618 | <1% | 125 | $7K | |
| 82728 | <1% | 148 | $6K | |
| 94060 | <1% | 20 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 65 | $6K |
| 72050 | <1% | 47 | $6K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 121 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 127 | $5K |
| 97161 | <1% | 36 | $5K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 115 | $5K |
| 82565 | <1% | 329 | $5K | |
| 86666 | <1% | 50 | $4K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 16 | $4K |
| 94727 | <1% | 20 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 79 | $3K |
| 94729 | <1% | 20 | $3K | |
| 97162 | <1% | 29 | $3K | |
| 84460 | <1% | 183 | $3K | |
| 82570 | <1% | 150 | $3K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 13 | $3K |
| 82951 | <1% | 54 | $3K | |
| 82607 | <1% | 53 | $3K | |
| 84134 | <1% | 34 | $3K | |
| 84450 | <1% | 132 | $2K | |
| 97035 | <1% | 26 | $2K | |
| 71101 | <1% | 19 | $2K | |
| 84520 | <1% | 154 | $2K | |
| 86753 | <1% | 46 | $2K | |
| 87802 | <1% | 60 | $2K | |
| 86140 | <1% | 62 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 14 | $2K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 40 | $2K |
| 77080 | <1% | 24 | $1K | |
| 71111 | <1% | 12 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 21 | $1K |
| ATP14 | <1% | 105 | $1K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 74 | $1K |
| 86787 | <1% | 29 | $839.09 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 14 | $831.60 |
| 99221 | <1% | 12 | $705.84 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 72 | $692.00 |
| 84550 | <1% | 35 | $582.15 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 16 | $573.39 |
| 86762 | <1% | 20 | $570.80 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 32 | $448.00 |
| 90461 | <1% | 21 | $404.10 | |
| 87075 | <1% | 14 | $385.11 | |
| 85652 | <1% | 13 | $309.96 | |
| 88312 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.